All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2022 Annual Meeting, the Lymphoma Hub spoke with Professor Catherine Thieblemont from the Hôpital Saint-Louis, Paris, France. We asked, How can we improve care for elderly patients with aggressive lymphomas?
How can we improve care for elderly patients with aggressive lymphomas?
Thieblemont explains our improved ability to predict treatment responses according to baseline risk and discusses how recent phase II trials have contributed to advances in this fast moving field.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
ASH 2018 | Phase III Alliance A041202 results on ibrutinib alone or with rituximab as front-line therapy in older CLL patients
In this multicenter, randomized,phase III trial bendamustine plus rituximab combination (arm 1) was compared against...
Should age affect eligibility for autologous stem cell transplant in elderly lymphoma patients?
This study demonstrated that elderly patients are still viable candidates for ASCT, with good clinical outcomes and acceptable expected toxicities.
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox